Results 21 to 30 of about 822,308 (398)

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Nature Medicine, 2016
Although mechanisms of acquired resistance of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancers to EGFR inhibitors have been identified, little is known about how resistant clones evolve during drug therapy.
A. Hata, M. Niederst, Hannah L. Archibald, María Gomez-Caraballo, Faria M. Siddiqui, Hillary E. Mulvey, Y. Maruvka, Fei Ji, Hyo-eun C Bhang, Viveksagar Krishnamurthy Radhakrishna, G. Siravegna, Haichuan Hu, S. Raoof, Elizabeth Lockerman, Anuj Kalsy, Dana Lee, Celina Keating, D. Ruddy, Leah J. Damon, A. Crystal, C. Costa, Z. Piotrowska, A. Bardelli, A. Iafrate, R. Sadreyev, F. Stegmeier, G. Getz, L. Sequist, A. Faber, J. Engelman   +29 more
semanticscholar   +1 more source

Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets. [PDF]

, 2019
BACKGROUND:The Human Epidermal Growth Factor Receptor (EGFR/HER1) can be activated by several ligands including Transforming Growth Factor alpha (TGF-α) and Epidermal Growth Factor (EGF).
Dutta, Pranabananda, Farias-Eisner, Robin, Nava, Miguel, Vadgama, Jaydutt V, Wu, Yanyuan, Zemke, Nathan R   +5 more
core   +5 more sources

Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

Tumor Biology, 2017
The finding of epidermal growth factor receptor tyrosine kinase inhibitors, which reflects a classical process of translational research, is a critical milestone for non-small-cell lung cancer treatment.
Shaohua Cui, Liyan Jiang
doaj   +1 more source

Prevalence of Epidermal Growth Factor Receptor Mutations in Patients with Non-Small Cell Lung Cancer in Turkish Population

Balkan Medical Journal, 2017
Aims: Epidermal growth factor receptor mutation analysis in non-small cell lung cancer is important for selecting patients who will receive treatment with tyrosine kinase inhibitors.
Gaye Güler Tezel, Ebru Şener, Çisel Aydın, Sevgen Önder   +3 more
doaj   +1 more source

Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium [PDF]

, 2014
Breast cancer risk factors and clinical outcomes vary by tumour marker expression. However, individual studies often lack the power required to assess these relationships, and large-scale analyses are limited by the need for high throughput, standardized
Ali, H Raza, Benitez, Javier, Blomqvist, Carl, Blows, Fiona M, Bolla, Manjeet K, Brinton, Louise, Brock, Ian W, Broeks, Annegien, Brook, Mark N, Caldas, Carlos, Couch, Fergus J, Coulson, Penny, Cox, Angela, Cross, Simon S, Daley, Frances, Dawson, Sarah-Jane, Devillee, Peter, Easton, Douglas F, Fagerholm, Rainer, Figueroa, Jonine, García-Closas, Montserrat, Gazinska, Patrycja, Heikkilä, Päivi, Hollestelle, Antoinette, Howat, William J, Johnson, Nicola, Jones, Louise, Kataja, Vesa, Kosma, Veli-Matti, Lissowska, Jolanta, Mannermaa, Arto, McDuffus, Leigh-Anne, Menéndez, Primitiva, Mesker, Wilma E, Miller, Jodi, Morris, Lorna, Nevanlinna, Heli, Olson, Janet E, Perez, Jose Ignacio Arias, Pharoah, Paul D, Pinder, Sarah, Provenzano, Elena, Reed, Malcolm W, Sanders, Joyce, Sawyer, Elinor J, Schmidt, Marjanka K, Seyaneve, Caroline M, Sherman, Mark E, Sironen, Reijo, van Deurzen, Carolien H M, Visscher, Daniel, Wesseling, Jelle   +51 more
core   +6 more sources

Arctigenin induced gallbladder cancer senescence through modulating epidermal growth factor receptor pathway

Tumor Biology, 2017
Gallbladder cancer has poor prognosis and limited therapeutic options. Arctigenin, a representative dibenzylbutyrolactone lignan, occurs in a variety of plants.
Mingdi Zhang, Shizhong Cai, Bin Zuo, Wei Gong, Zhaohui Tang, Di Zhou, Mingzhe Weng, Yiyu Qin, Shouhua Wang, Jun Liu, Fei Ma, Zhiwei Quan   +11 more
doaj   +1 more source

Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis

Thoracic Cancer, 2021
Background Differences in the resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor mutations are unknown.
Nobuaki Kobayashi, Seigo Katakura, Chisato Kamimaki, Kohei Somekawa, Nobuhiko Fukuda, Katsushi Tanaka, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Hongmei Piao, Takeshi Kaneko   +10 more
doaj   +1 more source

Triple negative breast cancer: new perspectives for targeted therapies [PDF]

, 2015
Breast cancer is a heterogeneous disease, encompassing a large number of entities showing different morphological features and having clinical behaviors.
Caruso, Davide, Frati, Luigi, Minozzi, Marina, Papa, Anselmo, Rossi, Luigi, Tomao, Federica, Tomao, Silverio, Vici, Patrizia, Zaccarelli, Eleonora   +8 more
core   +1 more source

Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Technology in Cancer Research & Treatment, 2020
Background: The efficacy of next-generation epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer who have failed first-generation epidermal growth factor receptor-tyrosine kinase inhibitors ...
Yi-Tian Qi MM, Yi Hou PhD, Liang-Chen Qi MD   +2 more
doaj   +1 more source

Application of preoperative ultrasound features combined with clinical factors in predicting HER2-positive subtype (non-luminal) breast cancer

BMC Medical Imaging, 2021
Background Human epidermal growth factor receptor2+ subtype breast cancer has a high degree of malignancy and a poor prognosis. The aim of this study is to develop a prediction model for the human epidermal growth factor receptor2+ subtype (non-luminal ...
Jin Zhou, An-qi Jin, Shi-chong Zhou, Jia-wei Li, Wen-xiang Zhi, Yun-xia Huang, Qian Zhu, Lang Qian, Jiong Wu, Cai Chang   +9 more
doaj   +1 more source